Looking forward to your response.
On June 13, 2023, the second stop of the “Guidelines for the Diagnosis and Treatment of Primary Osteoporosis” (2022) Interpretation Meeting and Rocaltrol® City Tour” jointly organized by Pharmanovia & Hesena was held in Lanhai Yuhua, Jinan City, Shandong Province The Grand Hotel was successfully held. The original intention of the “City Tour” activity is to enhance the guiding role of the “Guide” to clinicians and promote the whole society to pay attention to the prevention and treatment of osteoporosis. We hope to use this activity to assist the Osteoporosis and Bone Mineral Disease Branch of the Chinese Medical Association to jointly Promote the standardized diagnosis and treatment of osteoporosis, strengthen the linkage between hospitals and doctors at all levels, and improve the treatment and rehabilitation of osteoporotic fractures.
The meeting agenda was set around the “Guidelines for the Diagnosis and Treatment of Primary Osteoporosis” (2022), and academic leaders were invited, members of the Osteoporosis and Bone Minerals Branch of the Chinese Medical Association, and directors of the Osteoporosis and Bone Minerals Branch of the Shandong Medical Association Committee member, chairman of the Osteoporosis and Bone Mineral Salt Branch of Shandong Medical Association, Professor Xu Jin from the Department of Endocrinology of Shandong Provincial Hospital presided over the meeting, and three speakers with rich clinical experience introduced the diagnosis and treatment in the new guideline in detail related content, highlighted and shared the updated content of the “Guidelines for the Diagnosis and Treatment of Primary Osteoporosis” (2022), and sorted out the important role of Rocaltrol in the field of osteoporosis. Experts in the field of osteoporosis communicated with each other in the meeting, and shared hot information and treatment concepts of osteoporosis treatment. It fully embodies the purpose of “city meeting” to build a communication platform for doctors and promote the linkage between departments and hospitals.
After the meeting started, Professor Xu Jin first thanked all the participants for attending the meeting in spite of their busy schedules, and also thanked Pharmanovia & Hesenna for their continuous attention to the field of osteoporosis treatment, and introduced that the prevention and treatment of osteoporosis in my country is facing “one high and three lows”. The serious challenge is that the prevalence rate is high, but the awareness rate, diagnosis rate and treatment rate are low. Therefore, the whole society should pay more attention to the prevention and treatment of osteoporosis, especially graded diagnosis and treatment, bone density screening, early diagnosis, early medication and treatment, especially to prevent refracture after fracture. Then, the speaker, Professor Kong Lei from the Department of Endocrinology, Shandong Provincial Hospital, was invited to introduce the diagnosis and differential diagnosis of osteoporosis to the participating experts. Through the wonderful sharing of the guidelines, he especially pointed out the updated content, which provided many diagnoses for the doctors present. New ideas with differential diagnosis. And put forward diabetics, the elderly due to poor eyesight. Need to pay more attention to walking safety to prevent falls. Bone metabolism indicators are monitored every 2-3 months, and bone density is monitored once every 6-12 months.
The second topic of the meeting was Professor Chen Shihong, the chairman-designate of the Osteoporosis and Bone Mineral Disease Branch of Shandong Medical Association, and the Department of Endocrinology of the Second Hospital of Shandong University. Professor Chen Shihong gave an in-depth introduction to the main drugs for the prevention and treatment of osteoporosis. In particular, the effect of active vitamin D (Rocaltrol) on bone density was mentioned when supplementing the basic bone health supplement vitamin D in the basic measures. The safety of active vitamin D (Rocaltrol) has also been approved, and regular monitoring of blood calcium and urine calcium has been proposed.
Finally, Professor Sun Hongsheng from the Department of Rheumatology and Immunology of Shandong Provincial Hospital combined his own diseases in the Department of Rheumatology and Immunology, such as rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, Sjogren’s syndrome and systemic sclerosis. Active vitamin D (Rocaltrol) plays an important role in the treatment and rehabilitation of patients. At the same time, it is emphasized that patients are expected to use glucocorticoids for more than 3 months, and the dose is greater than 5mg for osteoporosis treatment intervention.
Prof. Xu Jin presided over the final discussion session. Many experts discussed the problems encountered in their clinical practice. Prof. Xu Jin once again emphasized that Rocaltrol(calcitriol) capsules are an indispensable therapeutic drug in the treatment of osteoporosis , It is widely used in sarcopenia, renal bone disease, and secondary osteoporosis. At the same time, Professor Xu Jin also mentioned that more than 20 years ago, diabetes gradually paid more attention to diagnosis and treatment. At present, diabetes diagnosis and treatment have been popularized and greatly improved. Professor Xu strongly appealed to medical staff and all walks of life to pay attention to and pay attention to osteoporosis, so as to improve the bone health of the whole people. Finally, Professor Xu Jin hoped that Pharmanovia & Hesenna would affirm the joint promotion of products, jointly promote the integration of diagnosis and treatment in the field of osteoporosis, and create health management in the whole field of osteoporosis, so as to bring good news to Chinese osteoporosis patients.